Hormone therapy for prostate cancer may affect cognition skills
Monday, July 28th, 2008 Posted in hormone therapy | No Comments »A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients--such as in the ability to recall and concentrate. Published in the September 1, ...
Fertility Issues In Patients With Prostate Cancer
Wednesday, July 23rd, 2008 Posted in hormone therapy, prostatectomy, radiation therapy | No Comments »PSA screening helps doctors to detect prostate cancer (CaP) in men at younger ages. In the online issue of the BJU International, a research team from Norway address the issues of fertility as related to prostate cancer therapies.In Norway, the ...
Bone Drug Reduces Fractures In Men Having Hormone Therapy For Prostate Cancer
Monday, July 21st, 2008 Posted in hormone therapy, prostate cancer | No Comments »Drugmaker Amgen Inc announced yesterday, Monday, that a large trial of its bone drug denosumab increased bone density and cut fractures in men with non-metastatic prostate cancer who were having hormone blocking therapy. A side effect of androgen deprivation therapy ...
Comorbidity reduces benefits of androgen suppression in prostate cancer
Sunday, July 20th, 2008 Posted in hormone therapy, radiation therapy | No Comments »The addition of androgen suppression therapy to radiation therapy for treatment of prostate cancer fails to improve survival among men with serious co-existing illness, according to a study in the Journal of the American Medical Association for January 23. Recent evidence ...
ED from prostate cancer hormone therapy treatable
Saturday, July 12th, 2008 Posted in hormone therapy | No Comments »A new study shows that a substantial minority of men receiving so-called androgen deprivation therapy, or ADT, for prostate cancer experience erectile dysfunction (ED). However, many respond well to ED therapy, doctors from Memphis have found. [ read full article ...
Hormonal therapy for localized tumors are not doing any favor to patients
Friday, July 11th, 2008 Posted in hormone therapy, prostate cancer | No Comments »One in six American men will be diagnosed with prostate cancer during his lifetime. Guidelines promulgated by national organizations recommend one of three approaches for treating such tumors: surgical removal, radiation therapy or expectant management, better known as watchful waiting. A ...
Hormone Blockers Don’t Help Early Prostate Cancer
Thursday, July 10th, 2008 Posted in hormone therapy | No Comments »Hormone therapy blocks production of testosterone, which feeds cancer cells. Widely used hormone-blocking drugs failed to improve survival in older men with early prostate cancer that hasn't spread, a study found. In fact, men given the drugs alone were slightly more ...
Hormone Therapy Shows Little Benefit Against Prostate Cancer
Thursday, July 10th, 2008 Posted in hormone therapy | No Comments »Survival rates no different than 'watchful waiting,' study shows. An increasingly common therapy used for localized prostate cancer may not bestow any survival benefits on the patient beyond those seen with a simple "wait-and-see" approach. Men taking androgen deprivation therapy, which shuts ...
Prostate cancer vaccines found to be more effective with hormone therapy
Thursday, July 10th, 2008 Posted in hormone therapy, prostate cancer | No Comments »According to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research, among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with ...
The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer Patients With Bone Metastases Treated With Zoledronic Acid
Monday, July 7th, 2008 Posted in hormone therapy | No Comments »Nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh and colleagues in the online version of Cancer. ZA is an intravenous bisphosphonate given to decrease skeletal related events ...